BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094031
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:http://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094031
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR